pubmed-article:1956212 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C0043251 | lld:lifeskim |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C0000854 | lld:lifeskim |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C0205082 | lld:lifeskim |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C0439228 | lld:lifeskim |
pubmed-article:1956212 | lifeskim:mentions | umls-concept:C0108941 | lld:lifeskim |
pubmed-article:1956212 | pubmed:issue | 8 | lld:pubmed |
pubmed-article:1956212 | pubmed:dateCreated | 1992-1-2 | lld:pubmed |
pubmed-article:1956212 | pubmed:abstractText | Peroral absorption of cefroxadine given to 7 24-h fasted trauma patients by nasogastric tube within the first day of admission was compared to that obtained in fasted healthy volunteers. The trauma patients exhibited significantly lower Cmax and reduced AUC. Even though rate and extent of bioavailability cannot be determined from these two different population groups since the total clearance must be assumed to be different in patients and healthy subjects, a reduced bioavailability is assumed based on pathophysiologic reflections. | lld:pubmed |
pubmed-article:1956212 | pubmed:language | eng | lld:pubmed |
pubmed-article:1956212 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1956212 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:1956212 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1956212 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1956212 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:1956212 | pubmed:month | Oct | lld:pubmed |
pubmed-article:1956212 | pubmed:issn | 0379-0355 | lld:pubmed |
pubmed-article:1956212 | pubmed:author | pubmed-author:HabererJ PJP | lld:pubmed |
pubmed-article:1956212 | pubmed:author | pubmed-author:RitschelW AWA | lld:pubmed |
pubmed-article:1956212 | pubmed:author | pubmed-author:AiacheJ MJM | lld:pubmed |
pubmed-article:1956212 | pubmed:author | pubmed-author:BeyssacEE | lld:pubmed |
pubmed-article:1956212 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:1956212 | pubmed:volume | 13 | lld:pubmed |
pubmed-article:1956212 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:1956212 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:1956212 | pubmed:pagination | 565-72 | lld:pubmed |
pubmed-article:1956212 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:meshHeading | pubmed-meshheading:1956212-... | lld:pubmed |
pubmed-article:1956212 | pubmed:year | 1991 | lld:pubmed |
pubmed-article:1956212 | pubmed:articleTitle | Peroral absorption of cefroxadine in patients within the first day after severe trauma: comparison to cefroxadine pharmacokinetics in fasted, healthy volunteers. | lld:pubmed |
pubmed-article:1956212 | pubmed:affiliation | Biopharmaceutics Department, Faculty of Pharmacy, Clermont-Ferrand, France. | lld:pubmed |
pubmed-article:1956212 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:1956212 | pubmed:publicationType | Comparative Study | lld:pubmed |